Momentum Trades

MomentumOptionsTrading.com Weekly Wrap for 4/27/2014

MomentumOptionsTrading.com Weekly Wrap for 4/27/2014

11:30pm (EST)

 

1.  Market Summary

2.  GW Pharmaceuticals (GWPH) – Smoking or Burning to the Ground?

3.  Earnings

4.  Weekly Wrap Portfolio Update 

5.  Week Ahead

 

(To view the charts, please log into the Members Area and go to the Weekly Wrap Premium section.)

 

= = = = = = = = = = = = = = =

 

1.  Market Summary  

 

“The three Dow stocks we said to watch offered great clues but a mixed picture as far as giving us direction for this week.

Goldman Sachs Group (GS, $152.72, down $3.26) fell $10.52 for the week and for those of you that shorted the May 155 puts (GS140517P00155000, $5.50, up $1.50), congratulations, you made a mint as they opened at $1.72 on Monday and were up over 200%.  We quoted last week as saying “a close below $160 would be bearish for Golden Slacks.”

Visa (V, $196.63, down $4.92) fell over $11 and last week’s chart work showed a back test to $195 could be coming.  Friday’s low checked-in at $194.84 and its hard to call it much better than that, folks.  Even better.  The May 190 puts (V140517P00190000, $4.50, up $1.55) opened at $1.95 on Monday and easily doubled by Friday’s close.

We listed both aforementioned put options on Goldman and Visa without call options in our Daily and these two trades were monsters.  For International Business Machines (IBM, $195.19, down $0.49) we listed call and put options as the chart was bullish and showed shares in a nice uptrend.  However, we felt a weak Dow would weigh on the stock.

The May 200 calls (IBM140517C00200000, $2.80, down $0.20) opened Monday at $2.05 after closing the previous Friday at $1.85.

The May 185 puts (IBM140517P00185000, $2.00, up $0.10) opened at $2.69 on Monday.

At current levels the trade would be slightly up if these options would have been purchased at the start of the week.  The real clue will be if shares can clear and hold $200 when IBM announce earnings this week or tumble below $190.  Last Thursday’s high was $199.21.

The Financial stocks have been stuck in the mud and we talked about JPMorgan’s (JPM, $55.30, down $0.10) and Wells Fargo’s (WFC, $48.08, up $0.37) results on Friday.  The zombies’ regulations have limited the banks’ ability to take on added risk but the problem is they are still not lending money because they want to get higher rates on the loans they do give out.  Additionally, credit scores and collateral are making it harder to get a loan (aside from an auto loan) as the banks hoard cash.

The Financial stocks needed to show strength on the run to resistance last week but instead are showing weakness.  The Financial Select Spiders (XLF, $21.28, down $0.26) stalled at $22.50 again and formed a “triple-top” in the process.  The chart shows three failed attempts at resistance ($22.50) and Friday’s close below $21.50 was bearish.  The XLF could test $20 on further weakness.

XLF42714

The Monday/ Friday closes have been streaking over the past 3 weeks as the bears have won the past 3 to start April following the bulls back-to-back wins to hold support at the end of March.

The bulls needed to win this past Friday’s session so this Monday will be crucial.  A higher Monday will likely keep the current trading range in play while a lower close would give the bears 4-straight M/F wins and would be a solid clue lower lows are coming.

Important Note:  The market will be closed this Good Friday.  Technically, the April options expire on the 19th but Thursday will be the last day to trade them.  Brokerage houses exercise the in-the-money options on Saturday to square the books.

We mentioned last week April is the best month for the Dow during the historical bull runs from November through April.  There will be a flood of earnings due out from the big boys that will certainly move the market needle as some of these stocks are heavily-weighted in the major indexes.

There are nearly a dozen companies we are looking at for possible earnings trades and while we certainly won’t take all of the trades listed in our Earnings section and Watch List, we could take one or two trades.  Specifically, we are watching Citigroup, Intel, Yahoo, PNC Financial Services Group, American Express, Google, IBM, SanDisk, Du Pont, Cypress Semiconductor, Fairchild Semiconductor and General Electric.

The flood of Initial Public Offerings (IPOs) this year and especially last week has also worried the bull haters as they say it adds froth to the market.

Ally Financial (ALLY, $24.20, up $0.22) was the largest IPO last week and perhaps the “greediest” as it still priced in the mid-$20’s.  The smart money was hoping shares would debut in the low $20’s to give back to the taxpayers that funded the company’s bailout back in 2008.

Instead, the zombies and investment bankers priced shares at $25 that was still in their expected range of $25 to $28.  Shares opened Thursday morning at $24.25 and kissed $24.79 before closing its first day of trading just 2 pennies south of $24.

Ally unloaded 95 million shares and was looking to get $2.5 billion from the offering.  The government used over $17 billion to keep the company afloat following the 2008 financial crisis debacle.  Ally, a General Motors (GM, $25.23, down $0.15) spinoff, did over $4 billion in sales last year and is an loan provider.

While we agree there have been some “sketchy” companies coming to the market, some of these IPO’s are worth looking into.  The difference from the dot.com IPO bubble from then and now is the companies going public today have earnings and revenue.

The charts are ugly, make no doubt about it, but there is a good chance the bulls rebound this week.

The Monday before April expiration is usually bullish as the blue-chips have been up 17 of the last 25 years.  This gives the market a 68% chance of finishing higher but over the past decade the Dow has been down 5 of the past 9 so its 50/50 if this factoid is added.

April expiration day is technically this Thursday and the good news here is that the blue-chips have traded higher 14 of the past 17 years with the Nasdaq up 13-straight.

We aren’t ready to give up on the bulls but if they don’t bounce back this week, we could be riding with the bears for a little while.  Remember, we are neither bullish or bearish at heart, we play the trend.  We would hate to see a continued pullback but there is just as much money to be made going short as there is long.

Our Daily portfolio has already started a put option position that is up over 200% and we have a few short candidates for our Weekly Wrap.  Like last week, the bulls have a little wiggle room left but not much.  (from 4/13/2014 Weekly Wrap…)

Following a shortened holiday week, April option expiration, geopolitical concerns and earnings, we mentioned Wall Street could be chasing the bulls as traders got back from vacation.  Most of the suit-and-ties took early vacations ahead of Easter and Spring break and figured they looked smart as the bears stretched support.  However, turnaround Tuesday’s have helped keep the year-long trading range intact despite the volatility and fund managers were chasing.

The bulls cleared the first layers of support into midweek and we mentioned in our Daily there would be some weakness into the end of the week.  There was with the bears grabbing the weekly win with Friday’s pullback.

The rest of April and beginning of May promises to be just as exciting with the bulls looking to clear resistance while the bears will be looking for Wall Street to sell in May and go away.  (continued…)

The Dow dropped 140 points, or 0.9%, to close at 16,361 on Friday.  The blue-chips traded down to 16,402 on Monday’s open before rebounding and pushing a high of 16,459.  We talked about resistance at 16,500-16,600 and Tuesday’s peak reached 16,565 with a finish at 16,514.  There was a tight 49-point trading on Wednesday that lead us to believe a pullback to support would come.  Thursday’s flat close was the first in nearly a decade for the Dow following a push to 16,541 with the exact finish of 16,501.75 from Wednesday.  Friday’s action was all downhill after a 2-point pop to 16,503 with a low of 16,333.  We talked specifically about the bulls holding 16,400-16,350 on a back test and the level held.  There is further help at 16,200 on another break below 16,350 followed by 16,100-16,000.  We could get aggressive with index put options on a drop below 16,000.  The bulls will need to clear 16,600 and we have said a close above this level gets 16,800-17,000 in play.  For the week, the Dow declined 47 points, or 0.3%, after starting at 16,408 and is down 215 points, or 1.3%, for 2014 (Dow ended 2013 at 16,576).

DOW42714

The S&P 500 tanked 15 points, or 0.8%, to settle at 1,863.  The index dipped a point to 1,873 to start the week and made a run at resistance at 1,875 while closing just below 1,872.  We have been mentioning another close above 1,875 might signal another test towards 1,900 and our 1,909 fluff target if cleared.  Tuesday’s run to 1,884 and finish at 1,879 got us excited but we prepared forma back test to 1,875-1,860.  Wednesday’s dip to 1,873 ended with a close at 1,875.39 with a run to 1,884 followed by a dip to 1,870 and close at 1,878 on Thursday.  The bears pushed a low of 1,859.70 on Friday and we wanted to see 1,860 hold into the weekend.  Mission accomplished.  However, if there is a drop below 1,850, and more importantly 1,840, we could use index put options to play another test to 1,825-1,800.  The S&P 500 came into the week at 1,864 and gave back a point-and-a-half, or 0.1%, by Friday’s close.  For the year, the index higher by 15 points, or 0.8% (S&P 500 ended 2013 at 1,848).

SPX42714

The Nasdaq declined 73 points, or 1.8%, to finish at 4,075 on Friday.  Tech tested 4,081 on Monday’s start and held 4,075 before the bulls made a run pst 4,100 to 4,121 into the close.  Tuesday’s trip to 4,170 was impressive but we talked about the 4,175-4,200 zone being a major hurdle.  Wednesday’s session was all red and we said if the bears cracked 4,150 there could be a flush out to 4,100-4,075.  The close at 4,126 was slightly bullish as Thursday’s open reached 4,177 but the fade to 4,107 and close at 4,148 was a good clues the bears would be fighting on Friday.  The Nasdaq was at 4,095 coming into the week and fell 20 points, or 0.5%.  Tech is lower by 101 points, or 2.4% year-to-date (Nasdaq ended 2013 at 4,176).

NAS42714

The Russell 2000 tumbled 21 points, or 1.9%, to end at 1,123 ahead of the weekend.   The small-caps traded to a low of 1,132 before recovering to close at 1,142.  The big test at 1,150 was met with ease at the index closed at 1,155 after pushing 1,157.  We said the bulls needed to clear 1,160 to get the green light to 1,175 but Wednesday’s negative session ended with another drop below 1,150 and close at 1,147.  We specifically said if 1,140 didn’t hold there could be a test to 1,125.  Thursday’s battle started with a run to 1,152 by the bulls that was greeted with a fight down to 1,136 by the bears.  The finish at 1,144 was shaky and Friday’s low touched 1,120.98 with a close just below 1,125.  There is further risk to 1,115-1,110 and we might use index put options on a drop below 1,100.  The Russell came into Monday’s open just below 1,138 and declined 15 points, or 1.3% for the week.  YTD, the small-caps have fallen 40 points, or 3.5% (Russell 2000 Dow ended 2013 at 1,163).

RUT42714

The S&P 500 Volatility Index ($VIX, 14.06, up 0.74) came into the week at 13.36 and we have been cheerleading that a close below 13.50 could lead to 12.50 and fresh all-time highs on the S&P.  Following a pop to 14.11 on Monday the VIX tested a low of 13.17 before ending at 13.25.  The bulls pushed 12.90 on Tuesday but the close at 13.19 suggested the S&P would have trouble holding 12.50.  Wednesday’s pop to 13.75 and Thursday’s jump to 14.08 ended with closes below 13.50.  However, Friday’s push to 15 and close above 13.50 was slightly bearish and could get 17.50 in play on further weakness.  A close above this level could confirm the bears are getting serious again.

VIX42714

Special Notice:  We hope everyone enjoyed the Easter holiday weekend and we are glad to be back.  It is rare we take a weekend off but on holidays we try to.  We still worked a ton of hours that weekend as our Daily newsletter always publishes when the market is open but we felt confident the bulls would hold support so there was no need to worry about Wall Street as we were in good shape. We had a ton of emails asking us about the holiday skip and we will do a better job of letting you know if we take a weekend off. (End)

Our chart work has been money all year and for those of you just joining us check out our February yearend targets for the major indexes that we will be talking about in upcoming weeks.

First, the near-term picture.

Trading ranges can be very emotional and over the years we have improved our skills in identifying them while they are developing.  They can have dramatic effects on your trading portfolio and why it is so important to do the daily homework, maybe trade a little less, and to work even harder to find the best of the best trades.

Once you have identified trading ranges and learn to manage them it will help you control your emotions and not to follow the crowd.

We have traded less with much better results during trading ranges because we wait for ALL of our technical signals to turn bullish or bearish to play the next possible trend.  The current choppiness, volatility, and whipsaw action can be confusing but is all typical action and reaction to trading ranges.

The goal in options trading is to hit the sweet spot during the uptrends AND downtrends with multiple triple-digit winners of profits up to 100%, 200%, and 300%.

It doesn’t matter if the trend is up or down, bullish or bearish, we play both sides.  Remember, most pros and the Average Joe’s don’t do chart work and study the market.  They only think about buying a stock and having it go up.  They don’t know how to short a stock or use put options to play pullbacks, selloffs, and corrections.

This is why use a variety of stock and option strategies for our Weekly Wrap portfolio and momentum option plays in our Daily.  The talking heads are mentioning momentum stocks are getting crushed and while that can be said, it works both ways.  Downward momentum can be just as powerful as upward momentum.  Take a look at our Daily 2008 Track Record to see some of the incredible returns our subscribers made using put options when the Dow was crashing 777 points in a day.

For investors that don’t know how to play the downside as well as the upside, they eliminate half of the playbook!  This is why we love trading options but we like buying stocks as well.  Using stocks and options to play up and down markets gives you ALL the tools needed to really play the Wall Street game.  If you don’t have them you will at some point join the crowd in saying Wall Street is rigged.

We mention all of this because we said the holiday shortened week could be THE week we would get a good feel on how the rest of April might play out.  It was, and while there looked like there could be a run to new highs, Friday’s pullback spooked more investors out of the market.

The bears did their best to come get us to join their side along with the herd from Wall Street that were betting on a continued market correction but we have trusted our chart work and haven’t flinch.

The prior Tuesday’s volatility was the wildest day of the year but like any chaotic situation, you have to have a game plan.  Without one, you get flushed out of trades or miss great opportunities to go long or short.

There are many theories on how the prior Tuesday’s turnaround started and the one that makes the most sense is that the Biotech stocks had fallen over 20% from their March high.  This is considered a bear market and buyers simply came in and started to buy the bottom.  The bounce into Easter was nice but the sector is still struggling.

The Nasdaq Biotech iShares (IBB, $223.96, down $5.66) made a run to $235 but clearly struggled with its 100-day MA.  The 200-day is just north of $221 and the dip to $207 could come into play on another dip below this level.  We could get aggressive with June or September put options on a drop below $220.

IBB42714

This will be one of the main clues we will be watching this week to see if the bulls can hold crucial support levels.

We will save the zombie talk and geopolitical concerns for another day or week as we hate talking politics but the headlines were a drag once again on the market.  We don’t want to spoil the good vibes that could come on another run past resistance and push to new highs.  The market needs the Russia/ Ukraine rhetoric to die down to start the week or there could be further weakness ahead.

The bulls need a good Monday/ Friday close this week and economic news could take center stage if talk of World War 3 simmers.  The Fed heads will be meeting again Tuesday/ Wednesday but there won’t be any zombie talk just a statement.  The ADP Employment report on Wednesday and Nonfarm Payrolls on Friday will likely influence market direction.

We are still expecting a possible push to all-times highs this week and this was our game plan from last year as Wall Street went away in May while the market traded higher in May.

In review, our downside targets to possibly go short or buy index put options are closes below Dow 16,000; S&P 1,840; Nasdaq 4,000; and Russell 1,100.

More conservative traders could roll with Dow 15,900; S&P 1,825; Nasdaq 3,925; and Russell 1,085 before getting aggressive.

Post these downside targets on your desktop or on the bathroom mirror (seriously) as they will help keep your emotions in check.  Until then, let’s see how the week plays out.

We have mentioned April is historically the Dow’s best month during the market’s bullish runs from November through April.

We mentioned in our Daily the breakeven points for April wins or losses are Dow 16,457; S&P 1,872; Nasdaq 4,199; Russell 1,173.

Given the current volatility, we expect more of the same this week as the bulls and bears fight over April’s close and battle for momentum into May.

In the meantime, we can look for a run to new highs or a continued trading range.  By keeping it simple, we can ignore the noise and focus on making money.

As we head from desk to press, futures are mixed:  Dow (xx); S&P 500 (xx); Nasdaq 100 (xx).

 

= = = = = = = = = = = = = = =

 

2. GW Pharmaceuticals (GWPH) – Smoking or Burning to the Ground?

Key of Technicals Used In Following Article

Technicalchart

GW Pharmaceuticals (GWPH) – Smoking or Burning to the Ground?

GW Pharmaceuticals (GWPH, $62.12, down $5.87) has had a wild ride this year.  It seems like after Colorado and Washington legalized marijuana, all marijuana stocks flew through the roof.  This stock is no exception.  But recently it pulled back.  Should we jump in?

Charta42714

Born in 1956, co-founder Dr. Geoffrey Guy received a bachelor of science in pharmacology from the University of London, a bachelor in medicine & bachelor in surgery (MBBS) from St. Bartholomew’s Hospital, and a Diploma of Pharmaceutical Medicine from the Royal Colleges of Physicians.  In 1985, he founded drug delivery company Ethical Holdings PLC and served as its Chairman and Chief Executive until 1997.  Ethical Holdings PLC listed on the Nasdaq in 1993, and after Elan Pharmacuticals (ELN) bought part of Ethical Holdings in 1999, it changed its name to Amarin Corporation PLC (ARMN).  Guy also co-founded plant-medicines company Phytopharm PLC in 1989 and served as its Chairman until 1997.  Phytopharm PLC listed on the London Stock Exchange under the ticker PYM.  It bought IXICO Limited in 2013 and changed its name to IXICO PLC (IXI.L).

In 1998, Guy teamed up with Dr Brian Whittle, who had also co-founded Phytopharm PLC with him, and formed GW Pharmaceuticals PLC to fill a serious unmet medical need.  Guy served as Chairman since its founding.  Whittle served as its Scientific Director until March 18, 2008.

In 1999, the House of Lords in the United Kingdom concluded that there was strong evidence supporting the potential therapeutic effects of components of the cannabis plant for the treatment of multiple sclerosis and the management of pain, and recommended that clinical trials be performed as soon as possible.  The House highlighted GW Pharmaceuticals’ research as holding significant promise.  The National Academy of Sciences in the United States came to similar conclusions about the medical use of cannabis.

Chartb42714

On May 1, 2013, the company went public with listing on NASDAQ stock exchange.  It offered 3.5 million shares at $8.90 a share, raising $31.15 million.  One ADR (American Depositary Receipt) equals 12 ordinary shares.  Thus, the $4.20 price mentioned above would be $50.40, and the $5.39 price would be $64.68, slightly above the closing price on the Nasdaq.

The company entered several marketing rights with various companies:

  • In      2003, it signed a license agreement with Bayer (BAYRY) for the marketing      rights to Sativex in the U.K.  The      agreement was expanded to include Canada later that year.  Under the agreement, it maintained a      significant share of long term product revenues while benefiting from a      signature fee.
  • In      2005, it signed a license agreement with Spanish drug giant Almirall S.A.      (ALM.MC), granting Almirall exclusive marketing rights to Sativex in      Europe except the U.K.  Under the      agreement, it maintained a significant share of long term product revenues      while benefiting from a £12 million signature fee and milestone payments      totaling up to £46 million.
  • In      2007, it granted Otsuka Pharmaceuticals, a subsidiary of Otsuka Holdings      of Japan, the U.S. development and marketing rights to Sativex.  Under the agreement, Otsuka provided $9      million for research.  Otsuka signed      a research extension agreement in 2010, providing an additional $12      million to cover research activities.
  • In      2011, it signed an agreement with Novartis (NVS) to distribute Sativex in      Australia, Asia (excluding China and Japan), the Middle-East, and      Africa.  Under the agreement, it      will receive an upfront payment of $5 million and will be eligible for      additional payments totaling $28.75 million upon the achievement of      certain approval and  commercial      milestones.  In addition, it will      receive royalties on net sales of Sativex.
  • In      2014, it signed an agreement with Ipsen Pharmaceuticals (IPN.PA) to      distribute Sativex in Latin America, excluding Mexico and the Islands of      the Caribbean.
  • Isreal’s      Neopharm Group holds exclusive commercial rights to Sativex in      Israel/Palestine.

Sativex is approved for use in the treatment of MS spasticity in 24 countries, including 18 countries in Europe.  Switzerland was the latest country to approve the drug, approving it on November 27, 2013.  The medicine is currently available on prescription in the U.K., Spain, Germany, Canada, Denmark, Norway, Israel, Austria, Poland, Sweden, Italy, and Finland with launches currently in preparation for a further eight European countries, as well as Australia, New Zealand, and Kuwait.  Regulatory filings are ongoing in nine other countries, principally in the Middle East where the company expects approvals during 2014.  The two maps below show its partners and where the drug has approval.

Chartc42714

In addition to Sativex, the company’s product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development.

chartd42714

On February 5, 2014, the company reported 1st quarter results for the three months ending December 31st.

  • Revenue      was $12.4 million, up from $5.2 million for the same quarter a year ago.
  • Net      loss after tax was $4.2 million, down from an after-tax profit of $2.1      million a year ago.
  • Orphan      Drug Designation was granted by the U.S. FDA for Epidiolex to treat Dravet      syndrome.
  • Orphan      Drug Designation was submitted to the FDA for Epidiolex to treat      Lennox-Gastaut syndrome.
  • Phase      2a trial data of GWP42003 for the treatment of ulcerative colitis is      ongoing and data expected in mid-2014.
  • Phase      2b dose ranging trial of GWP42004 in type-2 diabetes is expected to      commence in the 1st half of 2014
  • Phase      2a trial of GWP42003 for the treatment of schizophrenia is expected to      commence in the 1st half of 2014

On June 3rd before the bell, the company will report 2nd quarter results for the three months ending March 31st.  Analysts estimate the company will earn -$0.48 per share, down from -$0.26 a share a year ago.  However, revenue is expected to come in at $12 million, up from $7 million a year ago.

Charte42714

Chartf42714

At $62.12, the stock is below its low target of $65.00 made by the 5 analysts recorded by Thomson/First Call.  Mean target is $82.80, median target of $80.00, and high target is $97.00.  Using a scale of 1.0 as a strong buy and 5.0 as a sell, the average rating of the stock was 1.4, unchanged from a week ago.

 

Current Month

Last Month

Two Months Ago

Three Months Ago

Strong Buy

3

3

2

1

Buy

2

3

3

3

Hold

0

0

0

0

Underperform

0

0

0

0

Sell

0

0

0

0

 

= = = = = = = = = = = = = =

 

3.  Earnings  

The companies in BOLD, we are looking at as possible trades and we may list call or put options on them in our Daily Newsletter (subscription link).  If they become official recommendations, we sent out Trade Alerts or include them in our 9am and 1pm updates that come out during the week (Quotes are from 4/25/14 close)

 

Monday

Anworth Mortgage Asset (ANH)
Herbalife (HLF)
J & J Snack Foods (JJSF)
MicroStrategy (MSTR)
Plum Creek Timber (PCL)

Tuesday

3D Systems (DDD)
Boston Scientific (BSX)
Del Frisco’s Restaurant Group (DFRG)
Merck (MRK)
Big 5 Sporting Goods (BGFV)
DreamWorks Animation (DWA)
RF Micro Devices (RFMD)
Twitter (TWTR)

Wednesday

ADT Corporation (ADT)
Pitney Bowes (PBI)
TASER International (TASR)
Boston Beer Company (SAM)
Flextronics International (FLEX)
Hologic (HOLX)
LifeLock (LOCK)
Ruckus Wireless (RKUS)
WebMD Health (WBMD)

Thursday

Blue Nile (NILE)
Legg Mason (LM)
Monster Worldwide (MWW)
Pilgrim’s Pride (PPC)
World Wrestling Federation (WWE)        Short squeeze before open or test to teens?
Akamai Technologies (AKAM)
CubeSmart (CUBE)
Expedia (EXPE)
Kodiak Oil & Gas (KOG)
OpenTable (OPEN)
Seattle Genetics (SGEN)
Skullcandy (SKUL)
Tempur-Pedic International (TPX)

 

Friday

Knight Capital Group (KCG)
Madison Square Garden (MSG)
CVS Caremark (CVS)
Cooper Tire & Rubber Company (CTB)
Global Power Equipment Group (GLPW) 

 

= = = = = = = = = = = = =

 

4.  Weekly Wrap Covered Call Portfolio Update (Closing prices as of 4/25/14)

Our Weekly Wrap Closed Trade Track Record for 2014 is 12-3, or 80% win rate (97-10, or 91% win rate, overall since the start of 2011).

 

Coca-Cola (KO, $41.01, up $0.31) strangle option trade

June 41 calls (KO140621C00041000, $0.75, up $0.10)

Original Entry Price:  $0.60 (4/24/14)

Exit Target:  $1.20-$1.50

Return:  25%

Stop Target:  None

June 40 puts (KO140621P00040000, $0.50, down $0.05)

Original Entry Price:  $0.50 (4/24/14)

Exit Target:  $1.20

Return:  0%

Stop Target:  None

Action:  There was bevy of call buying in the June 41 calls on Friday as over 13,000 contracts traded hands.  We are trying to make 120% on either side of the trade, first, to lock-in profits and make it a risk-free trade.

The entry price fore both the calls and puts was $1.10.  At current levels the trade is up 14%.

We said we liked these options as a cheap way to play a possible move to $46 on the stock or a drop back below $40 to $38 over the near-term.

The bulls and bears are fighting hard over this stock and here is what we see in the chart.  The major MA’s are all converging just south of $39 and you can see the breakout above these levels earlier this month.  The 52-week high is at $43.43 and is on the verge of a multi-year breakout and we have said a run north of $45 could come.  On a numbers basis, the calls will double if shares reached $42.20 but here is where we are licking our chops.  If shares reach $43.43 the June 41 calls would be $2.43 in-the-money.  If we add a little time premium into the mix because these are June call options we can round up to $2.50-$2.60.  The entry price on the calls was 60 cents.  The return would be well over 300% on the calls.  At $45, a return of 500%-600% can be penciled-in on the calls as they would be worth of $4.

Of course, that is the best case but shares may not run that high as it is a low-beta stock so we still need to manage the trade.  We will likely close half the call options if they reach $1.20-$1.50 and ride the wave higher on the other half.  We would have tight stops in place to protect the profits if shares stall.

If there is a pullback by mid-June, that we see as a likely overall market pullback could happen by then, then a retest to $40, or worse could result.  The gap, or surge would likely be filled on a back test and a close below $40 would get the major MA’s in play.  This is where we said the beauty of the strangle option trade could play out.  Any close below $38.50 could lead to $37-$36.  At $39, the June 40 puts would be worth $1 and our return would be 100%.  If shares test $38, the puts would be worth $2, or 300%.

The stock yields 3% and could be considered a safe-haven if investors get spooked with a market pullback and may park some cash in the blue-chip.  Management keeps patting itself on their backs and high-fiving with more compensation.  Warren kept his voting shares out of the mix.  It is his poker hand and we respect that.  We like the turmoil surrounding the stock so let’s see how it plays out over the next couple months.

KO42714

Annaly Capital Management (NLY, $11.55, up $0.12) stock trade

Original Entry Price:  $11.39 (4/24/14)

Lowered Price from Selling Options/ Dividends  $11.39

Exit Target:  $15

Return:  1%

Stop Target:  $10

Current Dividend Yield: 10.5%

Action:  Support is at $11 and the 50-day MA.  Near-term resistance is at $12 and the 52-week high is at $15.96.

We have followed this company for over a decade back in our other financial writings over the years.  The company makes money on the yield spreads and as a REIT must return 90%-95% of their profits to shareholders.  As interest rates eventually rise, the company will make more money.  The current dividend yield is north of 10% and will dip if shares continue to move higher and will get it back under the radar on scan charts as a short candidate.  Sentiment is bearish on Wall Street for shares of Annaly but we trust the company and management.  The quarterly payout is 30 cents $1.20/ year) and the next dividend check should be sent in late June.

We could also sell the July 12 calls at some point as they are going for $0.70 and would provide even more safety by lowering our cost basis.  Investors would still get the June dividend payout as they would still own shares – unless they were called away (rare and still represents a profit).  As you can see there are a lot of ways to play this.

 

Hercules Offshore (HERO, $4.51, up $0.17)

May 4 calls (HERO140517C00004000, $0.55, up $0.10)

Original Entry Price:  $4.35 (4/14/14)

Lowered Price from Selling Options:  $3.80

Exit Target:  $5

Return:  19%

Stop Target:  $2

Action:  The May options expire in 20 days and we will likely get called away as shares are solidly above $4.  We sold in-the-money calls and expected a single-digit return as we wanted to make sure a “bottom” was in.  We are now considering adding another LEAP option trade and we are watching the January 5 calls 2015 (HERO15011700005000, $0.60, up $0.05) as a double-down bet.  Open Interest is over 5,000 contracts.

The bears have been attacking Hercules as shares are hovering near 52-week lows with risk to $4 on a break below $4.25.  A close above the 50-day MA, or $4.75, would be bullish and when we might add the LEAPs.

HERO42714

On 4/14/14 we recommended the stock at $4.35 and selling the May 4 calls for 55 cents.  If shares hold $4 by mid-May the stock will be “called-away” and the return will be 5%.

 

Kodiak Oil & Gas (KOG, $12.81, down $0.66) Stock Trade

Original Entry Price:  $13.25 (4/14/14)

Lowered Price from Selling Options:  $13.25

Exit Target:  $15

Return:  -3%

Stop Target:  $10

 

September 15 calls (KOG140920C00015000, $0.55, down $0.20) LEAP Trade

Original Entry Price:  $.0.72 (4/24/14)

Exit Target:  $1.45

Return:  -24%

Stop Target:  None

Action:  Near-term support is at $12.75 with backup at $12.50.  Shares have been pushing 52-week highs and we would like to see a run past $13.75 on the company’s earnings announcement on Thursday.

We have been providing coverage of this stock since February for our Daily and closed 2 KOG double-digit winning trades on Friday.  We have talked about this company as a takeover target and we believe shares can trip $15+ without one.  If shares can reach $17 by mid-September, the LEAP trade will easily make 100%-150%.

 

RF Micro Devices (RFMD, $7.99, down $0.55)

Original Entry Price:  $7.78 (4/14/14)

Lowered Price from Selling Options:  $7.78

Exit Target:  $10

Return:  3%

Stop Target:  $5

Action:  Shares surged 7% Thursday to close at $8.54 and 52-week highs (now resistance) but dropped 6% Friday.  Support is at $7.75 with backup at $7.50 and the 50-day MA.

RFMD42714

Alexza Pharmaceuticals (ALXA, $4.26, down $0.05) Covered Call Trade

Sold June 6 calls (ALXA140621C00006000, $0.05, flat)

Original Entry Price:  $5.53 (3/4/14)

Lowered Price from Selling Options:  $5.03

Exit Target:  $6+

Return:  -15%

Stop Target:  $3

Action:  Support is at $4 and a close below this level could lead to $3.75.  The first layer of resistance at $4.20 has cleared but much stronger hurdles are north of $4.80 and the major MA’s.

We opened this position in early March and we prepared for weakness by selling the June calls for $0.50.  Although we are slightly down on the trade, we don’t mind holding this low-priced gem through the current biotech turbulence as we like the company’s long-term prospects.

ALXA42714

On 3/4/2014 we recommended buying shares at $5.53 and selling the June 6 calls for 50 cents to lower our cost basis to $5.03.  If we are called away in mid-June at $6 the trade will make 20%.

 

Zynga (ZNGA, $4.08, down $0.27) Covered Call Stock Trade

Original Entry Price:  $5.63 (3/4/14)

Lowered Price from Selling Options:  $5.33

Exit Target:  $6+

Return:  -23%

Stop Target:  $3

Action:  Shares fell 6% Friday.  A close below $4 and the 200-day MA will likely lead to $3.60.  We would like to see shares move back above $4.25 this week.  We will wait until shares clear $5 to possibly write another option.

We have some backers on board this trade as S.A.C. Capital Advisors owns a 5.3% stake.  The company has some new games coming out over the next few months including a slick new version of Zynga Poker.  We believe the company is a takeover target based on the potential revenue poker could bring to the company although Zynga doesn’t plan to monetize anytime soon.  There is billions to be made if Zynga can monetize their poker app.

ZNGA42714

On 3/4/2014 we recommended buying shares at $5.63 and selling the April 6 calls for 30 cents to lower our cost basis to $5.33.

 

Discovery Laboratories (DSCO, $1.83, down $0.12) Covered Call Trade

Original Entry Price:  $2.42 (1/7/14)

Lowered Price from Selling Options:  $2.17

Exit Target:  $4.50-$5

Return:  -13%

Stop Target:  $1

Action:  Support is at $1.80-$1.75 and a move back above $2.00 would be bullish.

DSCO42714

On 1/7/2014 we recommended buying shares at $2.42 and selling the April 3 calls for 25 cents to lower our cost basis to $2.17.

 

Pizza Inn Holdings (PZZI, $5.61, down $0.07) Stock Trade

Original Entry Price:  $8.10 (10/11/13)

Lowered Price from Selling Options/ Dividends:  No options available

Exit Target:  $12+

Return:  -31%

Stop Target:  $5

Action:  The first wave of support at $5.75 was cracked and we mentioned a close below this level will get $5.50 in play again.  Resistance is at$6.  We may start SECOND positions soon as we don’t believe in averaging down trades.  It is tricks other newsletters use to lower the cost basis.  We have made profits of 42% and 19% since beginning coverage of the stock near the $3 level.

The company added 10 more units into their mix and now has 160 Pie Five shops opening this year and is expanding rapidly.  We believe this will be a $15-$20 stock in 1-2 years and insiders and mutual funds own nearly 40% of the company.

PZZI42714

Trades on HOLD (7):  AKS Steel Holding (AKS), DryShips (DRYS), Rambus (RMBS) on the verge of a breakout, Bebe Stores (BEBE) private equity offering coming north of $8?, Vivus (VVUS), Dendreon (DNDN), Galena Biopharma (GALE) LEAP Trade/ Stock Trade.

RMBS42714

 

= = = = = = = = = = = = = = =

 

5.  Week Ahead 

Here is a chart of the events for the week ahead:

Ecocal42714

Ecocalx42714

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Scroll to Top